海翔药业：参投公司创新药NWRD08注射液完成Ⅱ期临床首例受试者入组

Core Viewpoint - The announcement highlights the initiation of the Phase II clinical trial for China's first on-demand tumor therapeutic vaccine, NWRD08, developed by Nuowei Biotechnology, with participation from Haixiang Pharmaceutical's investment arm [1] Group 1: Company Developments - Haixiang Pharmaceutical has received a notification from its investment management firm, Beijing Guoxin Zhongshu Investment Management Co., Ltd. [1] - The company’s investment arm, Guoxin Haixiang, is participating in the clinical trial of NWRD08, which has officially started at multiple hospitals, including Peking Union Medical College Hospital [1] - The first subject has been enrolled and administered the vaccine as part of the clinical trial [1] Group 2: Industry Insights - The NWRD08 vaccine represents a significant advancement in the field of oncology, being the first of its kind in China for on-demand treatment [1] - The initiation of this clinical trial may indicate a growing focus on innovative cancer therapies within the biotechnology sector in China [1]